Harnessing the Power of a DNA-Delivery Platform to Address Chronic Inflammatory Diseases
Time: 11:30 am
day: Track B - Day 1 AM
Details:
- Advantages of DNA-Delivery, including safety, potential flexibility and manufacturing efficiency
- Demonstration of functionality with XT-150, addressing critical areas where other delivery modalities of IL-10 therapy have been ineffective
- Clinical program results for XT-150, a novel immunomodulatory gene therapy for osteoarthritis pain in Phase 2B development
